# First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer

> **NCT01097317** · PHASE2 · UNKNOWN · sponsor: **Wales Cancer Trials Unit** · enrollment: 52 (estimated)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Fatigue
- Lung Cancer
- Musculoskeletal Complications

## Interventions

- **DRUG:** carboplatin
- **DRUG:** vinorelbine tartrate
- **OTHER:** neuromuscular electrical stimulation
- **OTHER:** physiologic testing
- **PROCEDURE:** fatigue assessment and management
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01097317
- **Lead sponsor:** Wales Cancer Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2011-09
- **Final completion:** —
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2011-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097317, "First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01097317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*